GlassScriptPhysician profile
Angela D Reginelli
NPI 1972501229
$6,341.48
in general payments reported to CMS, 2019-2025
40 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $688 · 2021: $822 · 2022: $856 · 2023: $916 · 2024: $1,329 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,060 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,060.37 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,002.47 | 2019-2025 | Tavneos, Krystexxa, Evenity |
| Astrazeneca Pharmaceuticals LP | $657.91 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Otsuka America Pharmaceutical, INC. | $596.34 | 2019-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $373.80 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $365.19 | 2019-2025 | Ultomiris |
| Akebia Therapeutics INC | $334.23 | 2019-2025 | Vafseo, Auryxia |
| Mallinckrodt Hospital Products INC. | $291.06 | 2020-2025 | Acthar |
| Vifor Pharma, INC. | $275.14 | 2019-2025 | Veltassa, Korsuva |
| Novo Nordisk INC | $211.79 | 2020-2025 | Ozempic, Rivfloza |
| Lilly USA, LLC | $197.75 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $188.28 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $180.17 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Enterprises LLC | $159.15 | 2019 | |
| Opko Pharmaceuticals, LLC | $136.09 | 2019-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $133.57 | 2021-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Reginelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.